| A Study of the Safety and Pharmacokinetics of Single Ascending Oral Doses of INX-08189 in Healthy Subjects (NCT01159808) | Bristol-Myers Squibb | 2010-05-01 |
| An Anti-viral Combination Study With Japanese Hepatitis C Infection (HCV) Subject (NCT01051414) | Bristol-Myers Squibb | 2010-04-01 |
| Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-708163 (NCT01079819) | Bristol-Myers Squibb | 2010-04-01 |
| A Dose-Defining Study of CXL-1020 in Patients With Systolic Heart Failure (NCT01096043) | Bristol-Myers Squibb | 2010-04-01 |
| Safety Study of BMS-844421 for Treatment of Hypercholesterolemia (NCT01082562) | Bristol-Myers Squibb | 2010-04-01 |
| Multiple Dose Japanese Bridging Study (NCT01057030) | Bristol-Myers Squibb | 2010-03-01 |
| Korean Post-marketing Surveillance for Orencia® (NCT01583244) | Bristol-Myers Squibb | 2010-03-01 |
| Combination of Brivanib With 5-Fluorouracil/Leucovorin (5FU/LV) and 5-Fluorouracil/Leucovorin/Irinotecan (FOLFIRI) (NCT01046864) | Bristol-Myers Squibb | 2010-02-01 |
| Phase 1 Bioavailability Study of Apixaban Solution Formulation Relative to Apixaban Tablets in Healthy Subjects (NCT02034565) | Bristol-Myers Squibb | 2010-02-01 |
| Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin (NCT01030432) | Bristol-Myers Squibb | 2010-02-01 |
| Single Ascending Dose (BMS-813160) Study (NCT01049165) | Bristol-Myers Squibb | 2010-02-01 |
| A Study of BMS-833923 With Carboplatin and Etoposide Followed by BMS-833923 Alone in Subjects With Extensive-Stage Small Cell Lung Cancer (NCT00927875) | Bristol-Myers Squibb | 2010-02-01 |
| Drug Interaction Oral Contraceptive Pill (OCP) (NCT01063023) | Bristol-Myers Squibb | 2010-01-01 |
| Dose Escalation With Remicade® and Orencia® (NCT01141413) | Bristol-Myers Squibb | 2010-01-01 |
| Drug-Drug Interaction Study With Aricept® (Donepezil) (NCT01042314) | Bristol-Myers Squibb | 2010-01-01 |
| Drug-Drug Interaction to Study the Effect of BMS-708163 on Pharmacokinetics (PK) of Galantamine Extended Release (ER) (NCT01039194) | Bristol-Myers Squibb | 2010-01-01 |
| Multiple Ascending Dose Study of BMS-907351 (XL184) in Patients With Solid Tumors in Japan (NCT01018745) | Bristol-Myers Squibb | 2010-01-01 |
| Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma (NCT01024231) | Bristol-Myers Squibb | 2009-12-14 |
| Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha-2b and Ribavirin) in Japanese Patients (NCT01016912) | Bristol-Myers Squibb | 2009-12-01 |
| Efficacy, Pharmacokinetics, Safety, and Immunogenicity Study of Abatacept Administered Subcutaneously to Treat Rheumatoid Arthritis in Japanese Patients (NCT01001832) | Bristol-Myers Squibb | 2009-12-01 |
| Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care in Japanese Patients (Pegylated-interferon Alpha-2a and Ribavirin) (NCT01017575) | Bristol-Myers Squibb | 2009-12-01 |
| Predictors of Adherence to Orencia (NCT01136707) | Bristol-Myers Squibb | 2009-12-01 |
| Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care (NCT01012895) | Bristol-Myers Squibb | 2009-12-01 |
| Entecavir Plus Adefovir in Lamivudine-Resistant Patients (NCT00986778) | Bristol-Myers Squibb | 2009-12-01 |
| Hepatic Impaired Subjects Compared to Healthy Subjects Receiving Multi-dose BMS-650032 (NCT01019070) | Bristol-Myers Squibb | 2009-12-01 |
| Safety Study of BMS-816336 in Healthy Male Subjects (NCT00979368) | Bristol-Myers Squibb | 2009-11-01 |
| A Study of BMS-833923 With Cisplatin and Capecitabine in Inoperable, Metastatic Gastric, Gastroesophageal, or Esophageal Adenocarcinomas (NCT00909402) | Bristol-Myers Squibb | 2009-11-01 |
| Effect of Patient Cost Sharing on Treatment Discontinuation Among Rheumatoid Arthritis Patients (NCT01137851) | Bristol-Myers Squibb | 2009-11-01 |
| Methotrexate - Inadequate Response Device Sub-Study (NCT01173120) | Bristol-Myers Squibb | 2009-11-01 |
| Body Weight Effects on Glucophage's Efficacy in Chinese Diagnosed T2DM Patients (NCT00778622) | Bristol-Myers Squibb | 2009-11-01 |
| Multiple Dose Study In Treatment Naive Subjects Infected With Hepatitis C Virus (NCT00971308) | Bristol-Myers Squibb | 2009-10-01 |
| Study to Assess the Effect of BMS-790052 on the Pharmacokinetics of Ortho Tri-Cyclen® in Healthy Female Subjects (NCT00983957) | Bristol-Myers Squibb | 2009-10-01 |
| Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors (NCT00908024) | Bristol-Myers Squibb | 2009-10-01 |
| Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal Cancer (NCT00851045) | Bristol-Myers Squibb | 2009-10-01 |
| Abatacept Versus Adalimumab Head-to-Head (NCT00929864) | Bristol-Myers Squibb | 2009-10-01 |
| Changes in the Use of Opioids, Antidepressants, and Benzodiazepines in Rheumatoid Arthritis Patients Treated With Biologic Agents (NCT01137838) | Bristol-Myers Squibb | 2009-10-01 |
| Study of CCNU (Lomustine) Plus Dasatinib in Recurrent Glioblastoma (GBM) (NCT00948389) | Bristol-Myers Squibb | 2009-10-01 |
| Drug Interactions Between Voriconazole and Atazanavir Coadministered as Atazanavir/Ritonavir in Healthy Participants (NCT00833482) | Bristol-Myers Squibb | 2009-09-01 |
| Effect on the Electrocardiographic QT Interval Corrected for Heart Rate (QTc) in Healthy Subjects (NCT00979316) | Bristol-Myers Squibb | 2009-09-01 |
| Multiple Ascending Dose Study of BMS-754807 in Patients With Solid Tumors in Japan (NCT00898716) | Bristol-Myers Squibb | 2009-09-01 |
| Study of Ipilimumab and Dasatinib Combination Therapy in Patients With Chronic or Accelerated Chronic Myeloid Leukemia (NCT00732186) | Bristol-Myers Squibb | 2009-08-01 |
| Safety, Pharmacokinetics and Pharmacodynamics Study to Evaluate BMS-830216 in Obese Subjects (NCT00909766) | Bristol-Myers Squibb | 2009-08-01 |
| Comparison of Ipilimumab Manufactured by 2 Different Processes in Participants With Advanced Melanoma (NCT00920907) | Bristol-Myers Squibb | 2009-08-01 |
| Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC (NCT00908752) | Bristol-Myers Squibb | 2009-07-20 |
| Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL) (NCT00944905) | Bristol-Myers Squibb | 2009-07-01 |
| Safety, Pharmacokinetics and Pharmacodynamics Study of BMS-866949 in Healthy Subjects (NCT00949767) | Bristol-Myers Squibb | 2009-07-01 |
| Multiple Ascending Dose (MAD) Combination in Subjects With Multiple Myeloma (NCT00884546) | Bristol-Myers Squibb | 2009-07-01 |
| Ex Vivo Human Thrombosis Chamber Study (NCT00935506) | Bristol-Myers Squibb | 2009-07-01 |
| Combination Study of BMS-754807 and Herceptin® in Patients With Advanced or Metastatic Her-2-positive Breast Cancer (NCT00788333) | Bristol-Myers Squibb | 2009-07-01 |
| Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha and Ribavirin) (NCT00874770) | Bristol-Myers Squibb | 2009-06-01 |
| Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer (NCT00850577) | Bristol-Myers Squibb | 2009-06-01 |
| Safety and Hemodynamic Effects and Pharmacokinetics of CXL-1020 in Patients With Stable Heart Failure (NCT01092325) | Bristol-Myers Squibb | 2009-06-01 |
| A Study of BMS-863233 in Patients With Advanced and/or Metastatic Solid Tumors (NCT00886782) | Bristol-Myers Squibb | 2009-05-31 |
| Safety Study to Evaluate BMS-830216 in Healthy Subjects (NCT00878020) | Bristol-Myers Squibb | 2009-05-01 |
| A Study of FV-100 Versus Valacyclovir in Patients With Herpes Zoster (NCT00900783) | Bristol-Myers Squibb | 2009-05-01 |
| First Line Hepato Cellular Carcinoma (HCC) (NCT00858871) | Bristol-Myers Squibb | 2009-05-01 |
| A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease (NCT00890890) | Bristol-Myers Squibb | 2009-05-01 |
| Study of MDX-1411 in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma (NCT00730652) | Bristol-Myers Squibb | 2009-05-01 |
| Relative Bioavailability Study of Four Experimental Formulations for Alzheimer's Disease (NCT00901498) | Bristol-Myers Squibb | 2009-05-01 |
| Study of Immunotherapy to Treat Advanced Prostate Cancer (NCT00861614) | Bristol-Myers Squibb | 2009-05-01 |
| Economic Burden in Adult Patients Diagnosed With Rheumatoid Arthritis (RA) Receiving Treatment With Biologic Disease-modifying Antirheumatic Drugs (bDMARDs) (NCT01136694) | Bristol-Myers Squibb | 2009-05-01 |
| Study of Dasatinib and Bendamustine in Chronic Lymphocytic Leukemia (NCT00872976) | Bristol-Myers Squibb | 2009-05-01 |
| Multiple-Ascending Dose Study (NCT00892840) | Bristol-Myers Squibb | 2009-05-01 |
| Drug-Drug Interaction Study in Healthy Subjects (NCT00904059) | Bristol-Myers Squibb | 2009-05-01 |
| Systematic Review of Antiretroviral Treatments for Chronic Hepatitis B (CHB) (NCT01155427) | Bristol-Myers Squibb | 2009-05-01 |
| Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Combination With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Solid Tumors (NCT00793897) | Bristol-Myers Squibb | 2009-04-01 |
| Drug-Drug Interaction (DDI) w/Ketoconazole or Fluconazole (NCT00860275) | Bristol-Myers Squibb | 2009-04-01 |
| A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib (NCT00777036) | Bristol-Myers Squibb | 2009-03-20 |
| Single-Dose Pharmacokinetics of BMS-790052 in Participants With Hepatic Impairment (NCT00859053) | Bristol-Myers Squibb | 2009-03-01 |
| Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers (NCT00798252) | Bristol-Myers Squibb | 2009-03-01 |
| A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC (NCT00743938) | Bristol-Myers Squibb | 2009-03-01 |
| Phase III Acute Coronary Syndrome (NCT00831441) | Bristol-Myers Squibb | 2009-03-01 |
| An Experimental Medicine Study to Evaluate Serum Biomarkers of Lipid Metabolism (NCT00847782) | Bristol-Myers Squibb | 2009-03-01 |
| A Study of BMS-863233 in Patients With Hematologic Cancer (NCT00838890) | Bristol-Myers Squibb | 2009-03-01 |
| Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment (NCT00825955) | Bristol-Myers Squibb | 2009-02-17 |
| Drug-Drug Interaction - 3 Arm - Carboplatin/Paclitaxel, Dacarbazine (NCT00796991) | Bristol-Myers Squibb | 2009-02-01 |
| Multiple Ascending Dose (MDX1105-01) (NCT00729664) | Bristol-Myers Squibb | 2009-02-01 |
| Proof of Confidence Study of CCR2 Antagonist (BMS-741672) in Insulin Resistance (NCT00699790) | Bristol-Myers Squibb | 2009-02-01 |
| Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast Cancer (NCT00767520) | Bristol-Myers Squibb | 2009-02-01 |
| A Phase II, Multicenter, Double Blind, Placebo-Controlled Safety, Tolerability Study of BMS-708163 in Patients With Mild to Moderate Alzheimer's Disease (NCT00810147) | Bristol-Myers Squibb | 2009-02-01 |
| Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-779788 in Healthy Subjects (NCT00836602) | Bristol-Myers Squibb | 2009-02-01 |
| Cost of Monitoring Patients Treated With Vitamin K Antagonists in Spain (NCT02427516) | Bristol-Myers Squibb | 2009-01-01 |
| Ascending Multiple-Dose Study of BMS-817378 in Subjects With Advanced Cancers (NCT00792558) | Bristol-Myers Squibb | 2009-01-01 |
| Safety Evaluation of Dasatinib in Subjects With Scleroderma Pulmonary Fibrosis (NCT00764309) | Bristol-Myers Squibb | 2009-01-01 |
| A Rheumatoid Arthritis Study to Assess Early Response to Abatacept+MTX as Defined by Improvement of Synovitis Measures by Power Doppler Ultrasonography (NCT00767325) | Bristol-Myers Squibb | 2008-12-01 |
| Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis (NCT00570752) | Bristol-Myers Squibb | 2008-12-01 |
| A Multiple Ascending Dose Study of BMS-650032 in HCV Infected Subjects (NCT00722358) | Bristol-Myers Squibb | 2008-12-01 |
| A Study of Pharmacokinetics (PK) and Pharmacodynamics (PD) in Relation to Prednisolone in Healthy Males (NCT03198013) | Bristol-Myers Squibb | 2008-11-11 |
| Phase IIB Pilot of Atazanavir + Raltegravir (NCT00768989) | Bristol-Myers Squibb | 2008-11-01 |
| A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies (NCT00730639) | Bristol-Myers Squibb | 2008-10-30 |
| Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer (NCT00744497) | Bristol-Myers Squibb | 2008-10-01 |
| A Study of MDX-1106 to Treat Patients With Hepatitis C Infection (NCT00703469) | Bristol-Myers Squibb | 2008-10-01 |
| Safety Study of Multiple-dose of Gamma-secretase Inhibitor in Healthy Male Japanese and Healthy Elderly Japanese (NCT00828646) | Bristol-Myers Squibb | 2008-10-01 |
| Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor (NCT00754325) | Bristol-Myers Squibb | 2008-09-01 |
| Drug Interaction Study With a Potential Alzheimer's Disease Compound (NCT00726726) | Bristol-Myers Squibb | 2008-08-01 |
| Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic (NCT00696072) | Bristol-Myers Squibb | 2008-08-01 |
| A Phase IIIb Study to Compare Entecavir Plus Tenofovir vs. Adefovir Added to Continuing Lamivudine Therapy in Adult Patients With Lamivudine-Resistant Hepatitis B Infection (NCT00605384) | Bristol-Myers Squibb | 2008-08-01 |
| Safety Study to Evaluate BMS-767778 in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus (T2DM) (NCT00707590) | Bristol-Myers Squibb | 2008-08-01 |
| Phase I Study in China - Tolerability of a Single Dose of Abatacept 30 mg/kg (NCT00705367) | Bristol-Myers Squibb | 2008-08-01 |
| Study of MDX-1342 in Patients With Chronic Lymphocytic Leukemia (CLL) (NCT00593944) | Bristol-Myers Squibb | 2008-08-01 |